Rapamycin's Resurrection: A New Way to Target the Cancer Cell Cycle

doi:10.1093/jnci/93.20.1517

JNCI Journal of the National Cancer Institute 2001 93(20):1517-1519; doi:10.1093/jnci/93.20.1517
© 2001 by Oxford University Press

This Article

	Full Text
	Alert me when this article is cited
	Alert me if a correction is posted

Services

	Email this article to a friend
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new issues of the journal
	Add to My Personal Archive
	Download to citation manager
	Request Permissions

Google Scholar

	Articles by Garber, K.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Garber, K.

Social Bookmarking

	What's this?

Journal of the National Cancer Institute, Vol. 93, No. 20, 1517-1519, October 17, 2001
© 2001 Oxford University Press

NEWS

Rapamycin’s Resurrection: A New Way to Target the Cancer Cell Cycle

Ken Garber

CCI-779, a close analogue of rapamycin, has shown activity againsta wide range of cancers in preclinical models and in phase Itrials, and seven different phase II trials are under way. Somesuggest that it may be one of the most promising drugs in theanticancer pipeline.

"I’m excited," said Charles Sawyers, M.D., of the Universityof California at Los Angeles Jonsson Comprehensive Cancer Center."It’s a safe drug, it’s very precise in its action,it’s definitely a targeted therapy."

View larger version (107K):
[in this window]
[in a new window]

Dr. Charles Sawyers

The cancer research community is only now becoming aware ofCCI-779. But it is hardly new. The parent drug, rapamycin, wasdiscovered 30 years ago, and its activity against cancer wasrevealed back in the mid-1970s. All of the research on rapamycin,. . . [Full Text of this Article]

Add to CiteULike CiteULike Add to Connotea Connotea Add to Del.icio.us Del.icio.us What's this?

This article has been cited by other articles:

L. J. Costa and H. A. Drabkin
Renal Cell Carcinoma: New Developments in Molecular Biology and Potential for Targeted Therapies
Oncologist, December 1, 2007; 12(12): 1404 - 1415.
[Abstract] [Full Text] [PDF]

L. Wu, D. C. Birle, and I. F. Tannock
Effects of the Mammalian Target of Rapamycin Inhibitor CCI-779 Used Alone or with Chemotherapy on Human Prostate Cancer Cells and Xenografts
Cancer Res., April 1, 2005; 65(7): 2825 - 2831.
[Abstract] [Full Text] [PDF]

L. Lal, Y. Li, J. Smith, A. Sassano, S. Uddin, S. Parmar, M. S. Tallman, S. Minucci, N. Hay, and L. C. Platanias
Activation of the p70 S6 kinase by all-trans-retinoic acid in acute promyelocytic leukemia cells
Blood, February 15, 2005; 105(4): 1669 - 1677.
[Abstract] [Full Text] [PDF]

J. Huang, H. Zhu, S. J. Haggarty, D. R. Spring, H. Hwang, F. Jin, M. Snyder, and S. L. Schreiber
Finding new components of the target of rapamycin (TOR) signaling network through chemical genetics and proteome chips
PNAS, November 23, 2004; 101(47): 16594 - 16599.
[Abstract] [Full Text] [PDF]

J. R. Rohde, S. Campbell, S. A. Zurita-Martinez, N. S. Cutler, M. Ashe, and M. E. Cardenas
TOR Controls Transcriptional and Translational Programs via Sap-Sit4 Protein Phosphatase Signaling Effectors
Mol. Cell. Biol., October 1, 2004; 24(19): 8332 - 8341.
[Abstract] [Full Text] [PDF]

E. Raymond, J. Alexandre, S. Faivre, K. Vera, E. Materman, J. Boni, C. Leister, J. Korth-Bradley, A. Hanauske, and J.-P. Armand
Safety and Pharmacokinetics of Escalated Doses of Weekly Intravenous Infusion of CCI-779, a Novel mTOR Inhibitor, in Patients With Cancer
J. Clin. Oncol., June 15, 2004; 22(12): 2336 - 2347.
[Abstract] [Full Text] [PDF]

W.-C. Noh, W. H. Mondesire, J. Peng, W. Jian, H. Zhang, J. Dong, G. B. Mills, M.-C. Hung, and F. Meric-Bernstam
Determinants of Rapamycin Sensitivity in Breast Cancer Cells
Clin. Cancer Res., February 1, 2004; 10(3): 1013 - 1023.
[Abstract] [Full Text] [PDF]

V. I. Brown, J. Fang, K. Alcorn, R. Barr, J. M. Kim, R. Wasserman, and S. A. Grupp
Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling
PNAS, December 9, 2003; 100(25): 15113 - 15118.
[Abstract] [Full Text] [PDF]

F. Lekmine, S. Uddin, A. Sassano, S. Parmar, S. M. Brachmann, B. Majchrzak, N. Sonenberg, N. Hay, E. N. Fish, and L. C. Platanias
Activation of the p70 S6 Kinase and Phosphorylation of the 4E-BP1 Repressor of mRNA Translation by Type I Interferons
J. Biol. Chem., July 18, 2003; 278(30): 27772 - 27780.
[Abstract] [Full Text] [PDF]

Z.D. Sharp, W.-H. Lee, A. Y. Nikitin, A. Flesken-Nikitin, Y. Ikeno, R. Reddick, A. G. Richardson, and J. F. Nelson
Minimal effects of dietary restriction on neuroendocrine carcinogenesis in Rb+/- mice
Carcinogenesis, February 1, 2003; 24(2): 179 - 183.
[Abstract] [Full Text] [PDF]

T. Decker, S. Hipp, I. Ringshausen, C. Bogner, M. Oelsner, F. Schneller, and C. Peschel
Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin
Blood, January 1, 2003; 101(1): 278 - 285.
[Abstract] [Full Text] [PDF]

				L. Wu, D. C. Birle, and I. F. Tannock Effects of the Mammalian Target of Rapamycin Inhibitor CCI-779 Used Alone or with Chemotherapy on Human Prostate Cancer Cells and Xenografts Cancer Res., April 1, 2005; 65(7): 2825 - 2831. [Abstract] [Full Text] [PDF]

				L. Lal, Y. Li, J. Smith, A. Sassano, S. Uddin, S. Parmar, M. S. Tallman, S. Minucci, N. Hay, and L. C. Platanias Activation of the p70 S6 kinase by all-trans-retinoic acid in acute promyelocytic leukemia cells Blood, February 15, 2005; 105(4): 1669 - 1677. [Abstract] [Full Text] [PDF]

				J. Huang, H. Zhu, S. J. Haggarty, D. R. Spring, H. Hwang, F. Jin, M. Snyder, and S. L. Schreiber Finding new components of the target of rapamycin (TOR) signaling network through chemical genetics and proteome chips PNAS, November 23, 2004; 101(47): 16594 - 16599. [Abstract] [Full Text] [PDF]

				J. R. Rohde, S. Campbell, S. A. Zurita-Martinez, N. S. Cutler, M. Ashe, and M. E. Cardenas TOR Controls Transcriptional and Translational Programs via Sap-Sit4 Protein Phosphatase Signaling Effectors Mol. Cell. Biol., October 1, 2004; 24(19): 8332 - 8341. [Abstract] [Full Text] [PDF]

				E. Raymond, J. Alexandre, S. Faivre, K. Vera, E. Materman, J. Boni, C. Leister, J. Korth-Bradley, A. Hanauske, and J.-P. Armand Safety and Pharmacokinetics of Escalated Doses of Weekly Intravenous Infusion of CCI-779, a Novel mTOR Inhibitor, in Patients With Cancer J. Clin. Oncol., June 15, 2004; 22(12): 2336 - 2347. [Abstract] [Full Text] [PDF]

				W.-C. Noh, W. H. Mondesire, J. Peng, W. Jian, H. Zhang, J. Dong, G. B. Mills, M.-C. Hung, and F. Meric-Bernstam Determinants of Rapamycin Sensitivity in Breast Cancer Cells Clin. Cancer Res., February 1, 2004; 10(3): 1013 - 1023. [Abstract] [Full Text] [PDF]

				V. I. Brown, J. Fang, K. Alcorn, R. Barr, J. M. Kim, R. Wasserman, and S. A. Grupp Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling PNAS, December 9, 2003; 100(25): 15113 - 15118. [Abstract] [Full Text] [PDF]

				F. Lekmine, S. Uddin, A. Sassano, S. Parmar, S. M. Brachmann, B. Majchrzak, N. Sonenberg, N. Hay, E. N. Fish, and L. C. Platanias Activation of the p70 S6 Kinase and Phosphorylation of the 4E-BP1 Repressor of mRNA Translation by Type I Interferons J. Biol. Chem., July 18, 2003; 278(30): 27772 - 27780. [Abstract] [Full Text] [PDF]

				Z.D. Sharp, W.-H. Lee, A. Y. Nikitin, A. Flesken-Nikitin, Y. Ikeno, R. Reddick, A. G. Richardson, and J. F. Nelson Minimal effects of dietary restriction on neuroendocrine carcinogenesis in Rb+/- mice Carcinogenesis, February 1, 2003; 24(2): 179 - 183. [Abstract] [Full Text] [PDF]

				T. Decker, S. Hipp, I. Ringshausen, C. Bogner, M. Oelsner, F. Schneller, and C. Peschel Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin Blood, January 1, 2003; 101(1): 278 - 285. [Abstract] [Full Text] [PDF]